DOWN-REGULATION OF GALECTIN-8 AND ITS LIGAND ALCAM (?ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE?, CD166) REDUCES IN VIVO TUMOR GROWTH IN A MURINE MODEL OF BREAST CANCER

FERRAGUT, FÁTIMA; COLOMBO, LUCAS L.; SÁNCHEZ-TERRERO, CLARA; VACHETTA, VANINA; WOLFENSTEIN-TODEL, CARLOTA; TRONCOSO, MARÍA F.; RABINOVICH, GABRIEL A.; ELOLA, MARÍA T.

Ciudad Autónoma de Buenos Aires

Congreso; REUNIÓN CONJUNTA DE SOCIEDADES DE BIOCIENCIAS; 2017

Galectin-8 (Gal-8) is a ?tandem-repeat?-type galectin, with two carbohydrate recognition domains. We previously showed that the activated leukocyte cell adhesion molecule (ALCAM), which is a cell adhesion molecule, serves as a Gal-8 ligand. The aims of this work were: 1) To analyze cell surface effects of the Gal-8/ALCAM axis on adhesion and migration of human MDA-MB-231 breast cancercells; 2) To investigate Gal-8 and ALCAM effects on cell proliferation and spheroid formation; 3) To evaluate Gal-8 and ALCAM effects in a murine model of breast cancer. We established MDA-MB-231 cell lines in which Gal-8 (MDA-shGal8) and/or ALCAM expression (MDA-shALCAM) were stably knocked-down with specific shRNA;scrambled-shRNA was used for controls (MDA-shControl). Our results showed that cell adhesion onto immobilized Gal-8 was significantly reduced after ALCAM silencing in MDA-shALCAM (26.3±7.0%) and MDA-shALCAM-shGal8 (25.6±6.8%) as compared to MDA-shControl cells (100%), p